Rhabdomyolysis induced by orlistat
10.3760/cma.j.cn114015-20191213-01055
- VernacularTitle:奥利司他致横纹肌溶解症
- Author:
Dongxue WANG
1
;
Jiqiu HOU
;
Feng XU
Author Information
1. 吉林大学第二医院药学部，长春 130041
- Publication Type:Journal Article
- Keywords:
Orlistat;
Anti-obesity agents;
Rhabdomyolysis;
Creatine kinase
- From:
Adverse Drug Reactions Journal
2020;22(10):581-582
- CountryChina
- Language:Chinese
-
Abstract:
A 39-year-old male patient took orlistat 0.12 g thrice daily for weight loss. More than 4 months after medication, he developed muscle soreness of limbs and weakness of both lower limbs, with lower limb muscle strength at grade 3. Laboratory tests showed alanine aminotransferase (ALT) 65 U/L, aspartate aminotransferase (AST) 125 U/L, myoglobin>3 997 μg/L, creatine kinase (CK) 2 889 U/L, CK-MB (CK-MB) 71 U/L, serum creatinine (Scr) 1 418 μmol/L, urine protein (+++), and urine occult blood (+). Rhabdomyolysis caused by orlistat was considered. Orlistat was stopped and symptomatic treatments such as rehydration, alkaline urine, and diuretics were given. Seven days later, the patient′s symptoms were improved and the muscle strength of his lower limbs returned to grade 4. Laboratory tests showed ALT 52 U/L, AST 68 U/L, myoglobin 1 737 μg/L, CK 475 U/L, Scr 657 μmol/L, urine protein (+), and urine occult blood (-). One month later, the muscle strength of his lower limbs returned to grade 6. Laboratory tests showed ALT 35 U/L, AST 38 U/L, myoglobin 624 μg/L, and CK 192 U/L. The symptoms of myalgia and weakness of lower limbs did not recur.
